A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes |
| |
| Authors: | M.?Campone mailto:mario.campone@ico.unicancer.fr" title=" mario.campone@ico.unicancer.fr" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,N.?Isambert,E.?Bourbouloux,H.?Roché,J.?Bonneterre,G.?Milano,P.?Fumoleau |
| |
| Affiliation: | 1.Centre René Gauducheau,Nantes-Saint-Herblain,France;2.Centre Georges-Fran?ois Leclerc,Dijon,France;3.INSERM CIC-P 803,Dijon,France;4.Institut Claudius Regaud,Toulouse,France;5.Centre Oscar Lambret,Lille,France;6.Centre Antoine Lacassagne,Nice,France |
| |
| Abstract: | ![]()
Purpose A phase I study was performed to determine the maximal tolerated dose (MTD), recommended dose (RD), safety and efficacy of vinflunine when combined with capecitabine in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes, with pharmacokinetic blood sampling to test potential drug–drug interactions. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
